Amicus Therapeutics, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Amicus Therapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Amicus Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Amicus Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amicus Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Amicus Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Amicus Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Amicus Therapeutics, Inc.'s pipeline products

Reasons to buy

- Evaluate Amicus Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Amicus Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Amicus Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Amicus Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amicus Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Amicus Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Amicus Therapeutics, Inc. Snapshot 5
Amicus Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Amicus Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Amicus Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Amicus Therapeutics, Inc. - Pipeline Products Glance 14
Amicus Therapeutics, Inc. - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Amicus Therapeutics, Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Amicus Therapeutics, Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Amicus Therapeutics, Inc. - Drug Profiles 19
migalastat hydrochloride 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
afegostat tartrate 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
duvoglustat hydrochloride + alglucosidase alfa 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
migalastat hydrochloride + Enzyme Replacement Therapy 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(migalastat hydrochloride + agalsidase alfa) 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
AT-3375 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ATB-200 + Chaperone 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Chaperone-ERT Combinations 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
laronidase + Chaperone 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Recombinant Enzyme For Lysosomal Storage Disorder 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Recombinant Enzyme For Gaucher Disease 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Amicus Therapeutics, Inc. - Pipeline Analysis 33
Amicus Therapeutics, Inc. - Pipeline Products by Target 33
Amicus Therapeutics, Inc. - Pipeline Products by Route of Administration 34
Amicus Therapeutics, Inc. - Pipeline Products by Molecule Type 35
Amicus Therapeutics, Inc. - Pipeline Products by Mechanism of Action 36
Amicus Therapeutics, Inc. - Recent Pipeline Updates 37
Amicus Therapeutics, Inc. - Dormant Projects 44
Amicus Therapeutics, Inc. - Company Statement 45
Amicus Therapeutics, Inc. - Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Amicus Therapeutics, Inc., Key Information 5
Amicus Therapeutics, Inc., Key Facts 5
Amicus Therapeutics, Inc. - Pipeline by Indication, 2014 8
Amicus Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
Amicus Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
Amicus Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2014 11
Amicus Therapeutics, Inc. - Partnered Products in Pipeline, 2014 12
Amicus Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13
Amicus Therapeutics, Inc. - Phase III, 2014 14
Amicus Therapeutics, Inc. - Phase II, 2014 15
Amicus Therapeutics, Inc. - Phase I, 2014 16
Amicus Therapeutics, Inc. - Preclinical, 2014 17
Amicus Therapeutics, Inc. - Discovery, 2014 18
Amicus Therapeutics, Inc. - Pipeline by Target, 2014 33
Amicus Therapeutics, Inc. - Pipeline by Route of Administration, 2014 34
Amicus Therapeutics, Inc. - Pipeline by Molecule Type, 2014 35
Amicus Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 36
Amicus Therapeutics, Inc. - Recent Pipeline Updates, 2014 37
Amicus Therapeutics, Inc. - Dormant Developmental Projects,2014 44
Amicus Therapeutics, Inc., Subsidiaries 52